



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Cheng *et al.*

App. No. 10/081,969

Filed: Feb. 22, 2002

For: Novel Oncolytic Adenoviral Vectors

Art Unit: TBD

Examiner: TBD

Confirmation No. 4496

Atty Docket: 4-31704A

# 7/a  
Lita  
11/25/02

**PRELIMINARY AMENDMENT**

Commissioner of Patents  
Washington, D.C. 20231

Sir:

This paper is responsive to the Notice To File Missing Parts mailed March 27, 2002.

An Extension of Time for two months is hereby requested pursuant to 37 C.F.R. §1.136(a). Please charge Deposit Account No. 19-0134 (in the name of Novartis Pharmaceutical Corporation) in the amount of \$400.00 for payment of the extension fee. The Commissioner is authorized to charge any additional fees under 37 C.F.R. §1.17 that may be required, or credit any overpayment, to Novartis Pharmaceutical Corporation's Deposit Account No. 19-0134.

08/05/2002 MBERHE 00000020 10081969

02 FC:116 400.00 CH

**IN THE SPECIFICATION**

Please enter the enclosed paper Sequence Listing, pages 1-36, into the specification.

Please replace the below-identified paragraphs of the specification with the following replacement paragraphs set forth in re-written "clean form":

**Page 2, description of Figure 3:**

-- Figures 3A-3C: Sequence of Ar6pAE2fF from left and right ends of viral DNA.  
Regions of Ar6pAE2fF confirmed by DNA sequencing. Figures 3A-3B: Regions in first 1802